MARKET WIREMoomoo • 21h ago
Myomo(MYO) Stock Options Chain | Quotes & NewsMoomoo report covering Myomo Inc. (MYO) market action, institutional positioning, and fundamental catalysts.
Why MYO Stock dropped -3.23% Today — RQD Quant Desk Flash
$1.20 -3.23% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.19
Myomo Inc. (MYO) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $49.1M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on MYO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is MYO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Myomo Inc. (NYSE: MYO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.20 (-3.23% 1D, market cap $49.1M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, MYO ranks #769 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does MYO compare to COCH and APT in the Health Care sector?
▼
Within the Health Care sector (Industrial Specialties), MYO carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 65.7%, and ROIC of -35.0%. By comparison, COCH (Envoy Medical Inc. (Class A)) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $51.3M) and APT (Alpha Pro Tech Ltd.) posts a C- grade (61/100 RQD, P/E 16.2x, ROIC 6.7%, cap $55.1M). Among the 5-stock peer group, APT leads on earnings multiple (16.2x) while APT leads on capital efficiency (6.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for MYO?
▼
Per MYO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001369290), Myomo Inc. generated $40.9M in revenue (+25.7% YoY), -$15.6M in net income, and -$16.3M in free cash flow against $38.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.19 (-0.77%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MYO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY MYO SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+11/20 pts (35% of score)
FRED Regime × Technicals: 46% of 52W Range • RSI-14 at 43.7 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Whale & Options Positioning+7/20 pts (23% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.29-2.3% Next Q
39
Q2 (-2Q)Grade E$1.26-7.1% Next Q
36
Q3 (-1Q)Grade E$1.17+2.6% Next Q
34
CurrentGrade E$1.20-9.4% Hist 90D α
31
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a MYO Turnaround Squeeze
While MYO currently carries a cautious 31/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.41) and Max Pain ($1.26) forces dealer call-delta covering toward $1.97.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $MYO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MYO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why MYO Stock dropped -3.23% Today — RQD Quant Desk Flash
Myomo Inc. (MYO) dropped -3.23% to $1.20, trading at 46% of its 52-week range ($0.61 – $1.88). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 46% of its 52-week range ($0.61 – $1.88) with RSI-14 at 43.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.20 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 65.7% gross margin and $0 annual free cash flow.
Live MYO Headlines & Catalysts
MARKET WIREYahoo Finance • 1d ago
Myomo Appoints Mary-Katherine McClure as Chief Commercial OfficerYahoo Finance report covering Myomo Inc. (MYO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
To pay taxes only, Myomo (MYO) officer plans to sell 3,133 shares as stock grants vest.Stock Titan report covering Myomo Inc. (MYO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com India • 1d ago
Myomo CMO Harry Kovelman sells $20,136 in company stock By Investing.comInvesting.com India report covering Myomo Inc. (MYO) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Spotlight On 3 Penny Stocks With Market Caps As Low As $10MSimply Wall St report covering Myomo Inc. (MYO) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 1d ago
Despite Fast-paced Momentum, RXO (RXO) Is Still a Bargain StockYahoo Finance report covering Myomo Inc. (MYO) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 1d ago
Fast-paced Momentum Stock Best Buy (BBY) Is Still Trading at a BargainYahoo Finance report covering Myomo Inc. (MYO) market action, institutional positioning, and fundamental catalysts.
RISK WATCHhttps://www.dars.gov.et/ • 1d ago
MYO Q2 2026 Earnings: Wider-Than-Expected Loss Per Share, Yet Shares Edge Higher - New Analyst Coveragehttps://www.dars.gov.et/ report covering Myomo Inc. (MYO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 11d ago
PRISM MarketView Highlights Five Innovative Public Companies Supporting Strength and Mobility for National Physical Therapy MonthOrthoPediatrics, Omada Health, Enovis, Myomo and FIGS span the full arc of physical therapy, from childhood care and prevention to recovery and the professionals who deliver it NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) --
MARKET WIREYahoo • 15h ago
Myomo to Report Third Quarter 2026 Financial Results on November 9BURLINGTON, Mass., November 02, 2026--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders a
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MYO)
- ✓Walkthrough of MYO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
MYO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +39.53%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.30H $1.30L $1.20C $1.20VOL 200.1K
RES: $1.72SUP: $1.18SMA50: $1.41SMA200: $1.08
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
MYO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +25.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on MYO today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for MYO. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MYO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MYO)
Health Care Rank #769 of 1015
⚔️ COCH vs MYO Full Matrix →
1. Head-to-Head Health Care Peer Comparison (MYO vs. COCH, APT, NTRB, CNXU)
Industry: Industrial Specialties (55 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Myomo Inc. (MYO) ranks #769 by composite RQD confidence (31/100, grade E) and #749 by equity capitalization ($49.1M). Within this direct 5-issuer industry benchmark cohort, APT leads on earnings valuation at 16.2x trailing P/E, while APT leads on capital efficiency and profitability with 6.7% ROIC and 38.1% gross margin. APT currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with MYO at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MYO
ACTIVE
Myomo Inc. | E | 31/100 | — | 65.7% | -35.0% | -3.23% | $49.1M | Benchmark Subject |
| COCH Envoy Medical Inc. (Class A) | D- | 36/100 | — | -30.0% | -35.0% | +0.30% | $51.3M | /coch-vs-myo → |
| APT Alpha Pro Tech Ltd. | C- | 61/100 | 16.2x | 38.1% | 6.7% | +2.22% | $55.1M | /apt-vs-myo → |
| NTRB Nutriband Inc. | D- | 37/100 | — | 27.8% | -35.0% | +1.75% | $76.6M | /ntrb-vs-myo → |
| CNXU Conexeu Sciences Inc. | D- | 43/100 | — | — | — | -5.51% | $77.0M | /cnxu-vs-myo → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001369290 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Myomo Inc. (MYO) reported GAAP revenue of $40.9M (+25.7% vs. FY2024 revenue of $32.6M , and +112.7% cumulative change since FY2023) , GAAP net income of -$15.6M, operating cash flow of -$14.5M, and free cash flow of -$16.3M (-249.5% YoY). On the balance sheet, MYO closed FY2025 with $38.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $40.9M | -$15.6M | -$14.5M | -$16.3M | $38.6M | — |
| FY2024 (FY) | 2024-12-31 | $32.6M | -$6.2M | -$3.3M | -$4.7M | $42.2M | — |
| FY2023 (FY) | 2023-12-31 | $19.2M | -$8.1M | -$6.2M | -$6.2M | — | — |
3. MYO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs MYO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Myomo Inc. (NYSE: MYO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.20 (-3.23% 1D, market cap $49.1M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, MYO ranks #769 in composite RQD confidence.
How does MYO compare to COCH and APT in the Health Care sector?
Within the Health Care sector (Industrial Specialties), MYO carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 65.7%, and ROIC of -35.0%. By comparison, COCH (Envoy Medical Inc. (Class A)) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $51.3M) and APT (Alpha Pro Tech Ltd.) posts a C- grade (61/100 RQD, P/E 16.2x, ROIC 6.7%, cap $55.1M). Among the 5-stock peer group, APT leads on earnings multiple (16.2x) while APT leads on capital efficiency (6.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for MYO?
Per MYO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001369290), Myomo Inc. generated $40.9M in revenue (+25.7% YoY), -$15.6M in net income, and -$16.3M in free cash flow against $38.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is MYO trading relative to its 50-day, 200-day, and 52-week technical levels?
MYO last traded at $1.20 (-3.23% on volume of 301,444 shares), positioning the stock -14.89% below its 50-day simple moving average ($1.41) and +11.11% above its 200-day simple moving average ($1.08). Across its 52-week range of $0.61 to $1.88, MYO sits at the 46.5% percentile with a 14-day RSI of 43.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.05 to $1.35).
ROARABLE RATING BRIEF • RQD 31/100 (E)
✓ SEC XBRL & RQD VERIFIED
MYO — Myomo Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Myomo Inc. (MYO) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.20 (-3.23% 1D, market capitalization $49.1M).
- Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 65.7%, operating margin of -35.2%, and free cash flow yield of —.
- Whale 13F & Options Flow (7/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (11/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Myomo Inc. (MYO) is a NYSE-listed issuer classified under the Health Care sector and the Industrial Specialties industry. Per the market data, the company reports a gross margin of 65.7%, indicating a high-margin product or service mix at the gross level. Specific product lines, customer segments, and revenue mechanics are — The profile section gives a market capitalization of $0.1B, which is consistent in scale with the $51.5M figure in market data.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Myomo Inc. (MYO) reported $40.9M in annual revenue (up from $32.6M in FY2024, +25.7% YoY) and -$15.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($19.2M revenue, -$8.1M net income) through FY2025, MYO scaled operating cash flow to -$14.5M and free cash flow to -$16.3M, backed by $38.6M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 7/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $0.61 – $1.88 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -35.2% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies are — Sector correlations beyond the stated Health Care / Industrial Specialties classification are — The main second-order item a prospective investor should watch is the link between the reported cash decline (from $24.4M to $14.
- Key Question #1: Can MYO sustain or expand its -35.2% operating margin and -35.0% ROIC against Industrial Specialties peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $40.9M and free cash flow of -$16.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is MYO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
MYO Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Myomo Inc. (MYO) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Moomoo • 21h ago
Myomo(MYO) Stock Options Chain | Quotes & News Moomoo report covering Myomo Inc. (MYO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Myomo Appoints Mary-Katherine McClure as Chief Commercial Officer Yahoo Finance report covering Myomo Inc. (MYO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
To pay taxes only, Myomo (MYO) officer plans to sell 3,133 shares as stock grants vest. Stock Titan report covering Myomo Inc. (MYO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com India • 1d ago
Myomo CMO Harry Kovelman sells $20,136 in company stock By Investing.com Investing.com India report covering Myomo Inc. (MYO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Spotlight On 3 Penny Stocks With Market Caps As Low As $10M Simply Wall St report covering Myomo Inc. (MYO) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Despite Fast-paced Momentum, RXO (RXO) Is Still a Bargain Stock Yahoo Finance report covering Myomo Inc. (MYO) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Fast-paced Momentum Stock Best Buy (BBY) Is Still Trading at a Bargain Yahoo Finance report covering Myomo Inc. (MYO) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago
MYO Q2 2026 Earnings: Wider-Than-Expected Loss Per Share, Yet Shares Edge Higher - New Analyst Coverage https://www.dars.gov.et/ report covering Myomo Inc. (MYO) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
MYO Bull vs. Bear Conversation Board — What's Your Call at $1.20?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MYO 🐻 33% BEARISH CONVICTION
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH
🎯 Target: $1.57 (+26.6%)
📌 Pinned Debate Revenue grew from $19.2M to $40.9M across the three reported fiscal years while gross margin stood at 65.7%.
Revenue grew from $19.2M to $40.9M across the three reported fiscal years while gross margin stood at 65.7%.. When you look under the hood at MYO, Fundamental Cash Engine is 3/20 with 65.7% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (7/20) has been quietly accumulating below $1.88. My 12M target is $1.57.
CapAlloc_Nerd 🐂 BULL
@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Industrial Specialties. If gross margin (65.7%) holds, EPS grows into the multiple faster than bears think.
BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH
🎯 Target: $0.95 (-23.4%)
Spot @ $1.24 Operating income of -$14.4M, FCF of -$16.3M, ROIC of -35%, and an Altman Z-Score of 0.2 point to cash burn and forensic balance-sheet r
Operating income of -$14.4M, FCF of -$16.3M, ROIC of -35%, and an Altman Z-Score of 0.2 point to cash burn and forensic balance-sheet risk.. Look at the math on MYO: paying current EV/EBITDA multiples for -35.0% ROIC and -35.2% operating margins leaves zero margin of safety if Industrial Specialties demand softens. I'd wait for a retest of $1.09 before getting long.